Effects of novel subtype selective M-current activators on spinal reflexes in vitro: Comparison with retigabine

The activation of Kv7 channels and the resulting M-current is a powerful mechanism to control neuronal excitability with profound effects in pain pathways. Despite the lack of specific data on the expression and role of these channels in nociceptive processing, much attention has been paid at exploring their potential value as targets for analgesia. Here we have characterized the spinal actions of two novel subunit selective Kv7 activators, ICA-069673 and ML213, and compared their effects to those of retigabine that acts with similar affinity on all neuronal Kv7 channels. Spinal reflexes were recorded in a mouse spinal cord in vitro preparation to allow the testing of the compounds on native spinal pathways at known concentrations. As retigabine, novel compounds depressed spinal segmental transmission with particularly strong effects on wind up, showing an adequate pro-analgesic profile. ML213 presented the highest potency. In contrast to retigabine, the effects of ICA-069673 and ML213 were blocked by XE-991 even at the highest concentrations used, suggesting specific effect on Kv7 channels. In addition, the effects of ICA-069673 on repetitive stimulation are consistent with a mode of action involving state or activity dependent interaction with the channels. Compared to retigabine, novel Kv7 openers maintain strong depressant effects on spinal nociceptive transmission showing an improved specificity on Kv7 channels. The differential effects obtained with these Kv7 openers may indicate the existence of several Kv7 conformations in spinal circuits.

[1]  J. Lopez-Garcia,et al.  M-current modulators alter rat spinal nociceptive transmission: an electrophysiological study in vitro , 2004, Neuropharmacology.

[2]  W. Löscher,et al.  D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures , 1996, Epilepsy Research.

[3]  I. Greenwood,et al.  One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders , 2013, British journal of pharmacology.

[4]  M. Berger,et al.  Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Jentsch.  Neuronal KCNQ potassium channels:physislogy and role in disease , 2000, Nature Reviews Neuroscience.

[6]  S. Olesen,et al.  The KCNQ5 potassium channel from mouse: a broadly expressed M-current like potassium channel modulated by zinc, pH, and volume changes. , 2005, Brain research. Molecular brain research.

[7]  B S Brown,et al.  KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. , 1998, Science.

[8]  M. Schwake,et al.  Expression profile and characterisation of a truncated KCNQ5 splice variant. , 2008, Biochemical and biophysical research communications.

[9]  S. Scherer,et al.  Kv7.5 is the primary Kv7 subunit expressed in C‐fibers , 2012, The Journal of comparative neurology.

[10]  Haibo Yu,et al.  Discovery, Synthesis, and Structure Activity Relationship of a Series of N-Aryl- bicyclo[2.2.1]heptane-2-carboxamides: Characterization of ML213 as a Novel KCNQ2 and KCNQ4 Potassium Channel Opener. , 2011, ACS chemical neuroscience.

[11]  Y. Jan,et al.  M Channel KCNQ2 Subunits Are Localized to Key Sites for Control of Neuronal Network Oscillations and Synchronization in Mouse Brain , 2001, The Journal of Neuroscience.

[12]  Nicole Schmitt,et al.  Differential Effects of ICA-27243 on Cloned KV7 Channels , 2010, Pharmacology.

[13]  A. Gil-Nagel,et al.  Retigabine as adjunctive therapy in adults with partial-onset seizures: Integrated analysis of three pivotal controlled trials , 2012, Epilepsy Research.

[14]  D. A. Brown,et al.  Molecular correlates of the M‐current in cultured rat hippocampal neurons , 2002, The Journal of physiology.

[15]  B. Jensen,et al.  The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. , 2003, European journal of pharmacology.

[16]  Meng Wu,et al.  Isoform-specific Prolongation of Kv7 (KCNQ) Potassium Channel Opening Mediated by New Molecular Determinants for Drug-Channel Interactions* , 2010, The Journal of Biological Chemistry.

[17]  S. Scherer,et al.  KCNQ2 Is a Nodal K+ Channel , 2004, The Journal of Neuroscience.

[18]  Mark J. Suto,et al.  N-Pyridyl and Pyrimidine Benzamides as KCNQ2/Q3 Potassium Channel Openers for the Treatment of Epilepsy. , 2011, ACS medicinal chemistry letters.

[19]  A. Dickenson,et al.  KCNQ/M Currents in Sensory Neurons: Significance for Pain Therapy , 2003, The Journal of Neuroscience.

[20]  D. Zamanillo,et al.  Effects of centrally acting analgesics on spinal segmental reflexes and wind‐up , 2015, European journal of pain.

[21]  J. Lopez-Garcia,et al.  Spinal Reflexes and Windup In Vitro: Effects of Analgesics and Anesthetics , 2016, CNS Neuroscience & Therapeutics.

[22]  Karin Dedek,et al.  Myokymia and neonatal epilepsy caused by a mutation in the voltage sensor of the KCNQ2 K+ channel , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Berkovic,et al.  A potassium channel mutation in neonatal human epilepsy. , 1998, Science.

[24]  R. Kaji,et al.  KCNQ channels mediate IKs, a slow K+ current regulating excitability in the rat node of Ranvier , 2006, The Journal of physiology.

[25]  R. Netzer,et al.  Investigations into the Mechanism of Action of the New Anticonvulsant Retigabine - Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels , 2000, Arzneimittelforschung.

[26]  Vann Bennett,et al.  A Common Ankyrin-G-Based Mechanism Retains KCNQ and NaV Channels at Electrically Active Domains of the Axon , 2006, The Journal of Neuroscience.

[27]  G. Rigdon,et al.  KCNQ potassium channels: drug targets for the treatment of epilepsy and pain , 2004 .

[28]  Holger Lerche,et al.  The New Anticonvulsant Retigabine Favors Voltage-Dependent Opening of the Kv7.2 (KCNQ2) Channel by Binding to Its Activation Gate , 2005, Molecular Pharmacology.

[29]  D. A. Brown,et al.  Muscarinic suppression of a novel voltage-sensitive K+ current in a vertebrate neurone , 1980, Nature.

[30]  L. Cribbs,et al.  Differential Activation of Vascular Smooth Muscle Kv7.4, Kv7.5, and Kv7.4/7.5 Channels by ML213 and ICA-069673 , 2014, Molecular Pharmacology.

[31]  L. Kumar,et al.  Vascular KCNQ (Kv7) Potassium Channels as Common Signaling Intermediates and Therapeutic Targets in Cerebral Vasospasm , 2013, Journal of cardiovascular pharmacology.

[32]  E. Christian,et al.  Differential Expression of KCNQ2 Splice Variants: Implications to M Current Function during Neuronal Development , 2001, The Journal of Neuroscience.

[33]  C. Rundfeldt,et al.  The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[34]  I. Szelenyi,et al.  Flupirtine, a re-discovered drug, revisited , 2013, Inflammation Research.

[35]  T. Friedrich,et al.  Molecular Determinants of KCNQ (Kv7) K+ Channel Sensitivity to the Anticonvulsant Retigabine , 2005, The Journal of Neuroscience.

[36]  J. Lopez-Garcia,et al.  Enhancing M Currents: A Way Out for Neuropathic Pain? , 2009, Front. Mol. Neurosci..

[37]  T. Jegla,et al.  Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells , 2001, British journal of pharmacology.

[38]  Retigabine-induced population primary afferent hyperpolarisation in vitro , 2006, Neuropharmacology.

[39]  M. Blanar,et al.  Functional Expression of Two KvLQT1-related Potassium Channels Responsible for an Inherited Idiopathic Epilepsy* , 1998, The Journal of Biological Chemistry.

[40]  D. A. Brown,et al.  Activation of Expressed KCNQ Potassium Currents and Native Neuronal M-Type Potassium Currents by the Anti-Convulsant Drug Retigabine , 2001, The Journal of Neuroscience.

[41]  R. Netzer,et al.  The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits , 2000, Neuroscience Letters.

[42]  I. Rivera-Arconada,et al.  Effects of M‐current modulators on the excitability of immature rat spinal sensory and motor neurones , 2005, The European journal of neuroscience.

[43]  B. Rudy,et al.  Differential Expression of Genes Encoding Subthreshold-Operating Voltage-Gated K+ Channels in Brain , 2001, The Journal of Neuroscience.

[44]  T. Jegla,et al.  Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. , 2000, Molecular pharmacology.